Literature DB >> 27196778

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.

Christopher A Hamm1, Diarmuid Moran2, Kakuturu Rao3, Patricia B Trusk3, Karen Pry3, Mark Sausen4, Siân Jones4, Victor E Velculescu5, Massimo Cristofanilli6, Sarah Bacus7.   

Abstract

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted next-generation sequencing (NGS) and IHC were performed to identify activated pathways in IBC tumor tissues. siRNA studies examined the impact of IBC genomic variants in cellular models. IBC tumor tissues were further characterized for immune infiltration and immune checkpoint expression by IHC. Genomic analysis identified recurrent alterations in core biologic pathways, including activating and targetable variants in HER/PI3K/mTOR signaling. High rates of activating HER3 point mutations were discovered in IBC tumors. Cell line studies confirmed a role for mutant HER3 in IBC cell proliferation. Immunologic analysis revealed a subset of IBC tumors associated with high CD8(+)/PD-L1(+) lymphocyte infiltration. Immune infiltration positively correlated with an NGS-based estimate of neoantigen exposure derived from the somatic mutation rate and mutant allele frequency, iScore. Additionally, DNA mismatch repair alterations, which may contribute to higher iScores, occurred at greater frequency in tumors with higher immune infiltration. Our study identifies genomic alterations that mechanistically contribute to oncogenic signaling in IBC and provides a genetic basis for the selection of clinically relevant targeted and combination therapeutic strategies. Furthermore, an NGS-based estimate of neoantigen exposure developed in this study (iScore) may be a useful biomarker to predict immune infiltration in IBC and other cancers. The iScore may be associated with greater levels of response to immunotherapies, such as PD-L1/PD-1-targeted therapies. Mol Cancer Ther; 15(7); 1746-56. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27196778     DOI: 10.1158/1535-7163.MCT-15-0353

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  21 in total

1.  PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.

Authors:  Anna R Michmerhuizen; Andrea M Pesch; Leah Moubadder; Benjamin C Chandler; Kari Wilder-Romans; Meleah Cameron; Eric Olsen; Dafydd G Thomas; Amanda Zhang; Nicole Hirsh; Cassandra L Ritter; Meilan Liu; Shyam Nyati; Lori J Pierce; Reshma Jagsi; Corey Speers
Journal:  Mol Cancer Ther       Date:  2019-08-14       Impact factor: 6.261

Review 2.  Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.

Authors:  Tsutomu Kawaguchi; Barbara A Foster; Jessica Young; Kazuaki Takabe
Journal:  J Mammary Gland Biol Neoplasia       Date:  2017-04-27       Impact factor: 2.673

Review 3.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

4.  Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.

Authors:  Jing He; Lei Huo; Junsheng Ma; Jun Zhao; Roland L Bassett; Xiaoping Sun; Naoto T Ueno; Bora Lim; Yun Gong
Journal:  Am J Clin Pathol       Date:  2018-02-17       Impact factor: 2.493

Review 5.  New Treatment Strategies for the Inflammatory Breast Cancer.

Authors:  Elena Vagia; Massimo Cristofanilli
Journal:  Curr Treat Options Oncol       Date:  2021-04-24

6.  Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.

Authors:  François Bertucci; Laurys Boudin; Pascal Finetti; Christophe Van Berckelaer; Peter Van Dam; Luc Dirix; Patrice Viens; Anthony Gonçalves; Naoto T Ueno; Steven Van Laere; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2021-05-23       Impact factor: 8.110

Review 7.  Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer.

Authors:  Riley J Morrow; Nima Etemadi; Belinda Yeo; Matthias Ernst
Journal:  Mediators Inflamm       Date:  2017-05-14       Impact factor: 4.711

Review 8.  Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Authors:  Ricardo Costa; Cesar A Santa-Maria; Giovanna Rossi; Benedito A Carneiro; Young Kwang Chae; William J Gradishar; Francis J Giles; Massimo Cristofanilli
Journal:  Oncotarget       Date:  2017-02-14

9.  Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer.

Authors:  Rui Luo; Weelic Chong; Qiang Wei; Zhenchao Zhang; Chun Wang; Zhong Ye; Maysa M Abu-Khalaf; Daniel P Silver; Robert T Stapp; Wei Jiang; Ronald E Myers; Bingshan Li; Massimo Cristofanilli; Hushan Yang
Journal:  NPJ Breast Cancer       Date:  2021-06-01

10.  Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.

Authors:  Erika J Crosby; Chaitanya R Acharya; Anthony-Fayez Haddad; Christopher A Rabiola; Gangjun Lei; Jun-Ping Wei; Xiao-Yi Yang; Tao Wang; Cong-Xiao Liu; Kay U Wagner; William J Muller; Lewis A Chodosh; Gloria Broadwater; Terry Hyslop; Jonathan H Shepherd; Daniel P Hollern; Xiaping He; Charles M Perou; Shengjie Chai; Benjamin K Ashby; Benjamin G Vincent; Joshua C Snyder; Jeremy Force; Michael A Morse; Herbert K Lyerly; Zachary C Hartman
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.